Immutep (ASX:IMM) receives fast track designation from FDA
12 Oct 2022 - Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses the FDA fast track designation received in first-line non-small cell lung cancer, the company's new Phase 2 trial in soft tissue sarcoma and the outlook ahead.